Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CollPlant Biotechnologies (CLGN) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for CollPlant Biotechnologies (CLGN) over the last 8 years, with Q3 2025 value amounting to -$108000.0.

  • CollPlant Biotechnologies' Change in Accured Expenses fell 10769.23% to -$108000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$36000.0, marking a year-over-year increase of 3684.21%. This contributed to the annual value of -$353000.0 for FY2024, which is 27303.92% down from last year.
  • According to the latest figures from Q3 2025, CollPlant Biotechnologies' Change in Accured Expenses is -$108000.0, which was down 10769.23% from $136000.0 recorded in Q2 2025.
  • In the past 5 years, CollPlant Biotechnologies' Change in Accured Expenses ranged from a high of $476000.0 in Q4 2022 and a low of -$627000.0 during Q3 2021
  • In the last 5 years, CollPlant Biotechnologies' Change in Accured Expenses had a median value of -$88000.0 in 2023 and averaged -$84368.4.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 43333.33% in 2021, then surged by 20258.62% in 2022.
  • CollPlant Biotechnologies' Change in Accured Expenses (Quarter) stood at -$464000.0 in 2021, then skyrocketed by 202.59% to $476000.0 in 2022, then tumbled by 31.09% to $328000.0 in 2023, then crashed by 90.24% to $32000.0 in 2024, then crashed by 437.5% to -$108000.0 in 2025.
  • Its Change in Accured Expenses stands at -$108000.0 for Q3 2025, versus $136000.0 for Q2 2025 and -$96000.0 for Q1 2025.